Overview

Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)

Status:
Terminated

Trial end date:
2021-02-26

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of participants with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS) who require mechanical ventilation.

Phase:

Phase 3

Details

Lead Sponsor:

Incyte Corporation

Treatments:

Janus Kinase Inhibitors